Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) has released its 2022 Cybersecurity Annual Report, emphasizing the company's commitment to enhancing cybersecurity measures in healthcare. The report focuses on transparency and collaboration, detailing efforts to protect patient safety and privacy amidst rising cyber threats like ransomware and phishing. Key highlights include BD's coordinated vulnerability disclosure processes, collaborations with cybersecurity working groups, and proactive measures against emerging risks. The report aims to empower customers by providing essential information on managing cyber risks effectively.
The Board of Directors of Becton, Dickinson and Company (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, scheduled for payment on March 31, 2023. This will benefit shareholders on record as of March 10, 2023, translating to an indicated annual dividend rate of $3.64 per share. BD remains a leader in global medical technology, focusing on enhancing health through improved medical discovery and diagnostics, serving healthcare providers worldwide.
BD (Becton, Dickinson and Company) has launched the 3rd Generation BD Kiestra™ Total Lab Automation System, designed to enhance laboratory efficiency and flexibility. This new robotic track system automates lab specimen processing, aiming to reduce manual tasks and turnaround times. The system features customizable configurations to fit various laboratory workflows and spaces, utilizing BD Synapsys™ informatics for integrated data analysis. Notable improvements include eliminating manual sorting and optimizing workflows, potentially impacting productivity positively.
BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular PCR assay to detect the Mpox virus. This authorization allows the BD MAX™ System users to conduct timely diagnostics, enhancing the ability to combat the Mpox outbreak, designated a global health emergency by the WHO. The BD MAX™ System can process up to 24 samples in under three hours, offering multiple tests for various infections. This development is part of BD's commitment to improving diagnostics and healthcare delivery.
BD (Becton, Dickinson and Company) will host a live webcast of its Annual Meeting of Shareholders on January 24, 2023, at 1 p.m. (ET). Investors can access the webcast via the BD investor relations website, and a replay will be available afterward. BD is a leading global medical technology company focused on improving health outcomes through innovative technology and solutions. The company has a workforce of 77,000 and operates worldwide to address critical global health issues.
BD (Becton, Dickinson and Company) has appointed Michelle Quinn as acting general counsel effective February 3, 2023. She succeeds Samrat Khichi, who is leaving for a new opportunity. Quinn has been with BD since 2019, serving as senior vice president and chief ethics officer. She will lead BD's Law Group and is expected to contribute to the company’s 2025 strategy. In related changes, Ami Simunovich and Chris DelOrefice will oversee new responsibilities, reporting directly to BD’s CEO, Tom Polen.
BD (Becton, Dickinson and Company) will release its financial results for the first quarter of fiscal year 2023 on February 2, 2023, at 6:30 a.m. ET. The results will cover the quarter ending on December 31, 2022, and will be available on their investor relations website. Following the release, management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and company strategy. BD is recognized as a leading global medical technology company committed to enhancing healthcare through innovative solutions.
BD (Becton, Dickinson and Company) released survey results showing a significant knowledge gap among U.S. women about cervical cancer causes and prevention. Conducted by Harris Poll, 71% of women reported delaying Pap tests, with minority groups disproportionately affected. Despite 91% claiming general health knowledge, many lack understanding of cervical cancer screenings, with 67% unaware that HPV causes most cervical cancers. The survey indicates a need for improved education and access to self-collection kits as 79% of women show interest in them.
BD (Becton, Dickinson and Company) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 12:45 pm Eastern Time. The live webcast will be available on the BD investor relations website, with a replay accessible post-event. BD is a global leader in medical technology, committed to advancing health care through innovative solutions and technology, showcasing its presence in numerous countries and focus on improving care delivery.
Summary not available.